GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
pharmaphorum22h
FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen
GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker this morning. The fast ...
pharmaphorum22h
FDA set to decide on GSK's gepotidacin antibiotic in March
The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years.
radii22h
Chinese Toothpaste’s Blackface Branding Getting a Long-Overdue Retirement
Though Darlie's English name changed in the 1980s, its racially-charged Chinese name has remained intact until today Darlie, the Chinese toothpaste brand infamous for its blackface packaging, will ...